



*10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011*

MANUFACTURERS
(alphabetically by country)

Dr Malika Almansouri

World-Wide Vaccine Registration Manager

GlaxoSmithKline Biologicals

Parc de la Noire Epine

Avenue Fleming, 20

Building W23

Wavre, B-1300

Belgium

Dr Stephane De Walque

Scientist

Regulatory Affairs

GlaxoSmithKline Biologicals

Parc de la Noire Epine

Avenue Fleming, 20

Building W23

Wavre, B-1300

Belgium

Dr Michel Duchêne

Vice President

Product Manufacturing Center of Excellence

GlaxoSmithKline Biologicals

Avenue Pascal, 2-6

Wavre, B-1300

Belgium

Dr Eunice Miranda

Director

Supranationals, Government Affairs & Public Policy

GlaxoSmithKline Biologicals

Parc de la Noire Epine

Avenue Fleming, 20

Building W23

Wavre, B-1300

Belgium

Mr Zhang Jin

Beijing Tiantan Biological Products Co. Ltd.

4 Sanjianfang Nanli,

Chaoyang District,

Beijing 100024

People's Republic of China



*10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011*

Ms Meng Li

Assistant Director, Project Coordinator
International Cooperation Department
China National Biotech Group (SINOPHARM CNBG)
26F, Fortune Tower A
No.4 Hui-Xin East Str
Chaoyang District
Beijing 100029
People's Republic of China

Professor Qihan Li

Director
Kunming Institute of Medical Biology
Peking Union Medical College
Hua Jong Dong
Kunming, 650107
People's Republic of China

Mr Zhongping Xie

Deputy Director
Kunming Institute of Medical Biology
Peking Union Medical College
Hua Jong Dong
Kunming, 650107
People's Republic of China

Ms Lingjiang Yang

Director
International Cooperation Department
Chengdu Institute of Biological Products
379#, Section 3, Jinhua Lu, Jinjiang District
Chengdu
Sichuan, 610023
People's Republic of China

Dr Miladys Limonta Fernández

Senior Project Manager
Biopharmaceutical technology department
Centre for Genetic Engineering and Biotechnology (CIGB)
Avenue 31 e/ 158 y 190
Cubanacan
Havana 10600
Cuba



*10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011*

Ms Gitte Stawski
Department Manager, Quality & Control
Statens Serum Institut
5 Artillerivej
2300 Copenhagen S
Denmark

Mr Niels Thulstrup
Director
Sales and Business Development
Statens Serum Institut
5 Artillerivej
2300 Copenhagen S
Denmark

Dr Joël Calmet
Sanofi Pasteur SA
2, Avenue Pont Pasteur
F-69367 Lyon Cedex 07
France

Ms Geneviève Galy
Director Industrial Production
Sanofi Pasteur SA
Campus Mérieux
1541, Avenue Marcel Mérieux
69280 Marcy l'Etoile
France

Mr Pascal Perrin
Sanofi Pasteur SA
2, Avenue Pont Pasteur
F-69367 Lyon Cedex 07
France

Dr Alain Sabouraud
Head of Pharmaceutical Affairs and Responsible Pharmacist
Pharmaceutical Affairs
Sanofi Pasteur SA
2, Avenue Pont Pasteur
F-69367 Lyon Cedex 07
France

Dr François Sandre
Sanofi Pasteur SA
2, Avenue Pont Pasteur
F-69367 Lyon Cedex 07
France



***10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011***

Dr Emmanuel Vidor
Rotavirus Project Leader
Sanofi Pasteur SA
2, Avenue Pont Pasteur
F-69367 Lyon Cedex 07
France

Mr Thomas Riedel
Vaccines International Region (VIR)
Head of Clusters
Africa, Middle East & UNICEF Account
Novartis Vaccines and Diagnostics GmbH
Emil-Von-Behring Strasse 76
35041 Marburg
Germany

Dr G.V.J.A. Harshavardhan
Director
Rotavirus Vaccine Development Project & International Affairs
Bharat Biotech International Limited
Genome Valley
Turkapally, Shameerpet (M)
Hyderabad, AP 500 078
India

Dr Rajesh Jain
Joint Managing Director
Panacea Biotec Ltd. Head Office
B-1 Extn./A-27
Mohan Cooperative Industrial Estate
Mathura Road
New Delhi 110044
India

Mr Rajinder Kumar Suri
Chief Executive-Biologicals
Panacea Biotec Ltd.
B-1 Extension A-27
Mohan Co-op. Industrial Estate, Mathura Rd
New Delhi
India



*10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011*

Prakash R. Sabde
Managing Director
Haffkine Bio Pharmaceutical Corporation
Acharya Donde Marg
Parel
Mumbai 400 012
India

Mr Sri S.V. Shankarwar
General Manager for Production
Haffkine Bio Pharmaceutical Corporation
Acharya Donde Marg
Parel
Mumbai 400 012
India

Mr Wadi Hidayat
Polio Vaccine Production Manager
Bio Farma
Jl. Pasteur 28
Bandung, 40161
Indonesia

Dr Mahendra Suhardono
Production Director
Bio Farma
Jl. Pasteur 28
Bandung, 40161
Indonesia

Dr Dori Ugiyadi
Senior Manager for Viral Vaccine Production
Bio Farma
Jl. Pasteur 28
Bandung, 40161
Indonesia

Dr Rosanna Cieri
Regulatory Affairs Manager
Novartis Vaccines & Diagnostics S.r.l.
Loc. Bellaria, Rosia
Sovicille
Siena 53018
Italy



*10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011*

Dr Toshiyuki Adachi

Chief, Quality Control Division of Technical Department

Japan Poliomyelitis Research Institute

5-34-4 Kumegawa

Higashi-murayama-Shi

Tokyo, 189-0003

Japan

Mr Ryuta Nomura

Deputy Executive Director

Central Institute for Experimental Animals (CIEA)

1430 Nogawa, Miyamae

Kawasaki, 216-0001

Japan

Mr Seiichirou Oyama

Vaccine Technology R&D Labs.

Takeda Pharmaceutical Company Limited

4720 Takeda

Mitsui

Hikari,

Yamaguchi, 743-8502

Japan

Dr Shudo Yamazaki

Director-General

Japan Poliomyelitis Research Institute

5-34-4 Kumegawa

Higashi-murayama-Shi

Tokyo, 189-0003

Japan

Dr José Bugarin González

Quality Control Director

**Laboratorios de Biológicos y Reactivos de México S.A de
C.V.**

Mariano Escobedo No 20 Col Popotla,

C.P. 11400, México D.F.

Mexico

Dr Rocio Cervantes Rosales

Director

National Institute of Virology

**Laboratorios de Biológicos y Reactivos de México S.A de
C.V.**

Amores 1240

Col. Del Valle 03100, México D.F.

Mexico



*10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011*

Jean-Pierre Amorij

Program Manager Vaccine Technology

RIVM - Vaccinology

Formulation and Analytical Research

Postbus 457,

3720 AL Bilthoven

The Netherlands

Dr Wilfried Bakker

Project Leader

Netherlands Vaccine Institute (NVI / RIVM)

Antonie van Leeuwenhoeklaan 9-11

3721 MA Bilthoven

The Netherlands

Dr Peter Belt Ph.D.

Manager Business Development

Netherlands Vaccine Institute (NVI / RIVM)

Antonie van Leeuwenhoeklaan 9-11

3721 MA Bilthoven

The Netherlands

Mr Wouter Diependaal

Manager

Customer Relations

Bilthoven Biologicals

Antonie van Leeuwenhoeklaan 9-11

3721 MA Bilthoven

The Netherlands

Dr John Lewis

Senior VP

Scientific Affairs

Crucell

Archimedesweg 4-6

2333 CN, Leiden

The Netherlands

Ms Gabriella Rolli

Program Director

Crucell

Archimedesweg 4-6

2333 CN, Leiden

The Netherlands



***10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011***

Dr Roeland Van Dam

Manager Corporate Development & Licensing

Bilthoven Biologicals

Antonie van Leeuwenhoeklaan 9-11

3721 MA Bilthoven

The Netherlands

Mr Nico van den Heuvel

Manager Technology Transfer

Bilthoven Biologicals

Antonie van Leeuwenhoeklaan 9-11

3721 MA Bilthoven

The Netherlands

Dr Alexander Kiktenko

Deputy Director on Quality

**Federal State Unitary Enterprise of Chumakov Institute of
Poliomyelitis and Viral Encephalitides of Russian Acad.**

Med. Sci.

P.O. Institute of Poliomyelitis

27th km. of Kiev Highway

Leninsky District

Moscow Region, 142782

Russian Federation

Dr Andrew E. Malkin

Chief of Quality Assurance Division

**Federal State Unitary Enterprise of Chumakov Institute of
Poliomyelitis and Viral Encephalitides of Russian Acad.**

Med. Sci.

P.O. Institute of Poliomyelitis

27th km. of Kiev Highway

Leninsky District

Moscow Region, 142782

Russian Federation

Dr Alexandra A. Sinyugina

Chief of Quality Control Division

**Federal State Unitary Enterprise of Chumakov Institute of
Poliomyelitis and Viral Encephalitides of Russian Acad.**

Med. Sci.

P.O. Institute of Poliomyelitis

27th km. of Kiev Highway

Leninsky District

Moscow Region, 142782

Russian Federation



*10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011*

Mr David Daout
International Affairs
Serum Institute of India Ltd.,
Chemin du Canal No. 5
1260, Nyon
Switzerland

Dr Diana Felnerova
Head of Regulatory Affairs Paediatric Vaccines Franchise
Regulatory Affairs Department
Berna Biotech/Crucell
Rehhagstrasse 79a
3018 Bern
Switzerland

Mr Yves Leurquin
Executive Vice President International and Government Affairs
Berna Biotech/Crucell
Rehhagstrasse 79a
3018 Bern
Switzerland

Dr Ulrich Maerki
Taconic Europe A/S
Hardstr.15
CH-5043 Holziken
Switzerland

Dr Stefano Malvolti
Global Policy Director
Novartis Vaccines & Diagnostics
Novartis Campus WSJ-210.2.20.18
CH-4056 Basel
Switzerland

Dr Olga Popova
Vice President
Government Affairs & Public Health
Berna Biotech/Crucell
Rehhagstrasse 79a
3018 Bern
Switzerland



*10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011*

Dr Michael Royals

Chief Science Officer
Head, Global Applications Development

Pharmajet Inc

400 Corporate Circle, Ste. N
Golden, Colorado 80401

United States of America

Dr Richard R. Stout

Executive Vice President, Chief Medical Officer

Bioject, Inc.

20245 SW 95th Avenue
Tualatin, Oregon 97062

United States of America

Dr Sherry Weigand

Senior Director
Strategic Product Planning Department

Takeda Pharmaceuticals Company Limited

One Takeda Parkway
Deerfield, IL 60015

United States of America

Dr Thi Luan Le

Deputy Director
**Center for Research and Production of Vaccines and
Biologicals**

135 Lo Duc
Hai Ba Trung
Hanoi
Viet Nam



*10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011*

NATIONAL REGULATORY AUTHORITIES (alphabetical by country)

Dr Geneviève Waeterloos

Head of Biological Standardization
Scientific Institute of Public Health
14, Rue Juliette Wytsmansstraat
Brussels, 1050
Belgium

Dr Sylvie Morgeaux

Head Of Viral Vaccine Control Unit
Agence Française de Sécurité Sanitaire de Produits de Santé
(AFSSAPS)
Direction des Laboratoires et des Contrôles
Unité de Contrôle des Médicaments Immunologiques
321, avenue Jean Jaurès
69007 Lyon
France

Dr Rumondang Simanjuntak

Senior GMP Inspector
Ministry of Health
National Agency of Drug and Food Control
Jalan Percetakan Negara No. 23
Jakarta Pusat, 10560
Indonesia

Dr Lucia Fiore

Research Director, Head Viral Vaccines Unit
Center for Immunobiologic Research and Evaluation (CRiVIB)
Istituto Superiore di Sanita
National Center for Immunobiological Research & Development
Viale Regina Elena 299
Roma, 00161
Italy

Dr Lorenzo Montrasio

Head of Biological Medicinal Products Unit
Evaluation and Registration Department 2
Agenzia Italiana del Farmaco (AIFA)
Via del Tritone 181
Roma, 00187
Italy



***10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011***

PARTNER AGENCIES

Mr Ian Lewis
Contracts Officer
Supply Division
UNICEF
Unicef Plads, Freeport
2100 Copenhagen
Denmark

Ms Meredith Shirey
Chief, Vaccine Center
Supply Division
UNICEF
Unicef Plads, Freeport
2100 Copenhagen
Denmark

Dr Brigitte Adjagba Toure
Senior Health Specialist (Polio)
UNICEF Liaison Officer
World Health Organization
20 Avenue Appia
CH-1211 Geneva 27
Switzerland

Mr Jalaa Abdelwahab
Health Specialist- Polio/Immunizations
Program Division, Health Section,
UNICEF
3 UN Plaza
NY, NY 10017
United States of America

Dr Darin Lee Zehrung
Associate Technical Officer
Program for Appropriate Technology in Health (PATH)
2201 Westlake Ave, Suite 200
Seattle, WA 98121
United States of America



*10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011*

OBSERVERS

Mr Ron Bellamy
Oliver Wyman
155 N. Wacker Drive, Suite 1600
Chicago, IL 60606
United States of America

Mr Gerard Cunningham
Senior Program Officer
Bill and Melinda Gates Foundation
1551 Eastlake Avenue East, Suite 100
Seattle, WA 98102-3706
United States of America

Dr John Boslego
Director
Vaccine Development Strategic Program
Program for Appropriate Technology in Health (PATH)
455 Massachusetts Ave, N.W., Suite 1000
Washington, DC 20001
United States of America

Dr Philip Minor
Head, Division of Virology
National Institute for Biological Standards and Control
(NIBSC) Health Protection Agency
Blanche Lane, South Mimms
Potters Bar, Herts EN6 3QG
United Kingdom

Dr Aurelia Nguyen
Director, Policy
Policy & Performance
GAVI Alliance
2 chemin des Mines
1202 Geneva
Switzerland

Mr James Platts
Associate Program Officer
Bill and Melinda Gates Foundation
1551 Eastlake Avenue East
Seattle, WA 98102-3706
United States of America



***10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011***

Mr Graegar Smith

Associate Partner

Oliver Wyman

155 N. Wacker Drive, Suite 1500

Chicago, IL 60606

United States of America

Ms Kim Swanson

Associate

Oliver Wyman

1166 Avenue of the Americas, 24th Floor

New York, NY 10036

United States of America



***10th WHO/UNICEF Informal Consultation with
OPV/IPV Manufacturers and National Regulatory Authorities
27 October 2011***

WHO SECRETARIAT

Dr R. Bruce Aylward, ADG PEC

Dr Jacqueline Fournier-Caruana, Scientist, IVB/QSS

Dr Hiromasa Okayasu, Medical Officer, POL/RAP

Dr Roland Sutter, Coordinator, POL/RAP

Dr Rudi Tangermann, Medical Officer, POL/SAM